治疗药物监测技术的现状与研究进展

娄晟; 李丹; 张霖峰; 李泽垚; 吕狄亚; 柴逸峰; 娄晟; 李丹; 张霖峰; 李泽垚; 吕狄亚; 柴逸峰

doi:10.12206/j.issn.2097-2024.202507003

[1]

中国药理学会治疗药物监测研究专业委员会. 治疗药物监测工作规范专家共识(2019 版)[EB/OL].(2021-06-11)[2025-11-07]. http://www.tdmchina.org/details/3XwylKu9g.html.

[2]

NGUYEN S T, HO D N, HUYNH T A H, et al. Development of UPLC–MS/MS method for the simultaneous quantification of valproic acid and phenytoin in human plasma and application to study pharmacokinetic interaction in epilepsy patients[J]. Heliyon, 2024, 10(13): e33630. doi: 10.1016/j.heliyon.2024.e33630

[3]

WANG Z H, LIU Z Y, et al. The impact of different immunosuppressants and acute immune rejection on clinical outcomes in diverse solid organ transplant recipients[J]. Front Immunol, 2026, 16: 1739468. doi: 10.3389/fimmu.2025.1739468

[4]

PATOCKA J, NEPOVIMOVA E, WU W D, et al. Digoxin: pharmacology and toxicology: a review[J]. Environ Toxicol Pharmacol, 2020, 79: 103400. doi: 10.1016/j.etap.2020.103400

[5]

FANG Z J, ZHANG H, GUO J C, et al. Overview of therapeutic drug monitoring and clinical practice[J]. Talanta, 2024, 266: 124996. doi: 10.1016/j.talanta.2023.124996

[6]

ATES H C, ROBERTS J A, LIPMAN J, et al. On-site therapeutic drug monitoring[J]. Trends Biotechnol, 2020, 38(11): 1262-1277. doi: 10.1016/j.tibtech.2020.03.001

[7]

UDOMKARNJANANUN S, FRANCKE M I, DE WINTER B C M, et al. Therapeutic drug monitoring of immunosuppressive drugs in hepatology and gastroenterology[J]. Best Pract Res Clin Gastroenterol, 2021, 54: 101756.

[8]

FILLER G, SMITH N. The need for tacrolimus assay standardization[J]. Ther Drug Monit, 2014, 36(6): 693-695. doi: 10.1097/FTD.0000000000000103

[9]

TUZIMSKI T, PETRUCZYNIK A. Review of chromatographic methods coupled with modern detection techniques applied in the therapeutic drugs monitoring (TDM)[J]. Molecules, 2020, 25(17): 4026. doi: 10.3390/molecules25174026

[10]

BURNS A N, GOLDMAN J L. A moving target: vancomycin therapeutic monitoring[J]. J Pediatr Infect Dis Soc, 2020, 9(4): 474-478.

[11]

ABDUL-AZIZ M H, BRADY K, COTTA M O, et al. Therapeutic drug monitoring of antibiotics: defining the therapeutic range[J]. Ther Drug Monit, 2022, 44(1): 19-31. doi: 10.1097/FTD.0000000000000940

[12]

邓阳, 肖亦莎, 李昕, 等. 氨基糖苷类抗生素治疗药物监测及其毒理机制研究进展[J]. 中国药理学与毒理学杂志, 2019, 33(12): 1085-1092. doi: 10.3867/j.issn.1000-3002.2019.12.010

[13]

JOHANNESSEN LANDMARK C, JOHANNESSEN S I, PATSALOS P N. Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects[J]. Expert Opin Drug Metab Toxicol, 2020, 16(3): 227-238. doi: 10.1080/17425255.2020.1724956

[14]

SOMMERFELD-KLATTA K, ZIELIŃSKA-PSUJA B, KARAŹNIEWCZ-ŁADA M, et al. New methods used in pharmacokinetics and therapeutic monitoring of the first and newer generations of antiepileptic drugs(AEDs)[J]. Molecules, 2020, 25(21): 5083. doi: 10.3390/molecules25215083

[15]

KNEZEVIC C E, MARZINKE M A. Clinical use and monitoring of antiepileptic drugs[J]. J Appl Lab Med, 2018, 3(1): 115-127. doi: 10.1373/jalm.2017.023689

[16]

Schoretsanitis G, Kane JM, Correll CU, Marder SR, Citrome L, Newcomer JW, et al. Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie[J/OL]. J Clin Psychiatry, 2020, 81(3): 19cs13169[2025-11-07]. https://www.psychiatrist.com/jcp/consensus-on-monitoring-blood-antipsychotic-levels/.

[17]

DING J, YANG L, MENG Z C, et al. Therapeutic drug monitoring of perospirone: The lowest effective plasma concentration in patients with schizophrenia[J]. Asian J Psychiatry, 2023, 90: 103832. doi: 10.1016/j.ajp.2023.103832

[18]

BOUSMAN C A, BENGESSER S A, AITCHISON K J, et al. Review and consensus on pharmacogenomic testing in psychiatry[J]. Pharmacopsychiatry, 2021, 54(1): 5-17. doi: 10.1055/a-1288-1061

[19]

AMSTUTZ U, HENRICKS L M, OFFER S M, et al. Clinical pharmacogenetics implementation consortium(CPIC)guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update[J]. Clin Pharmacol Ther, 2018, 103(2): 210-216. doi: 10.1002/cpt.911

[20]

SALMAN B, AL-KHABORI M. Applications and challenges in therapeutic drug monitoring of cancer treatment: a review[J]. J Oncol Pharm Pract, 2021, 27(3): 693-701. doi: 10.1177/1078155220979048

[21]

MIURA M. Personalized medicine for oral molecular-targeted anticancer drugs[J]. Folia Pharmacol Japonica, 2019, 153(2): 73-78. doi: 10.1254/fpj.153.73

[22]

MENZ B D, STOCKER S L, VEROUGSTRAETE N, et al. Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology[J]. Br J Clin Pharmacol, 2021, 87(2): 227-236. doi: 10.1111/bcp.14372

[23]

KLIMO P, CONNORS J M. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma[J]. Ann Intern Med, 1985, 102(5): 596-602. doi: 10.7326/0003-4819-102-5-596

[24]

ZHUANG W, ZENG Y, LIN X P, et al. Genetic and pharmacokinetic factors associated with imatinib-induced toxicities in gastrointestinal stromal tumors[J]. Pharmacogenomics J, 2025, 25: 32. doi: 10.1038/s41397-025-00391-0

[25]

Unveiling the underpinnings of various non-conventional ELISA variants: a review article[J/OL]. Expert Review of Molecular Diagnostics, 2022, 22(7)[2025-11-07]. https://www.tandfonline.com/doi/10.1080/14737159.2022.2117615.

[26]

SAITA T, YAMAMOTO Y, HOSOYA K, et al. An ultra-specific and sensitive sandwich ELISA for imatinib using two anti-imatinib antibodies[J]. Anal Chim Acta, 2017, 969: 72-78. doi: 10.1016/j.aca.2017.03.034

[27]

KOLLER D, VAITSEKHOVICH V, MBA C, et al. Effective quantification of 11 tyrosine kinase inhibitors and caffeine in human plasma by validated LC-MS/MS method with potent phospholipids clean-up procedure. Application to therapeutic drug monitoring[J]. Talanta, 2020, 208: 120450. doi: 10.1016/j.talanta.2019.120450

[28]

WU X Y, FU X K, LI A, et al. High-throughput quantification of tacrolimus in whole blood by acoustic ejection mass spectrometry: analytical validation and comparative assessment against conventional LC-MS/MS for therapeutic drug monitoring[J]. Clin Chim Acta, 2026, 588: 120986. doi: 10.1016/j.cca.2026.120986

[29]

ZHAO X, HAN S B, CHEN C, et al. Deep learning-assisted SERS platform for label-free detection of celecoxib in serum using ag@Pt@porous silicon Bragg mirror composite substrate[J]. Spectrochim Acta Part A Mol Biomol Spectrosc, 2026, 348: 127165. doi: 10.1016/j.saa.2025.127165

[30]

HOMOLA J. Surface plasmon resonance sensors for detection of chemical and biological species[J]. Chem Rev, 2008, 108(2): 462-493. doi: 10.1021/cr068107d

[31]

Wong CL, Olivo M. Surface Plasmon Resonance Imaging Sensors: A Review[J]. Plasmonics, 2014, 9: 809-824. doi: 10.1007/s11468-013-9662-3

[32]

QI M Y, LV D Y, ZHANG Y, et al. Development of a surface plasmon resonance biosensor for accurate and sensitive quantitation of small molecules in blood samples[J]. J Pharm Anal, 2022, 12(6): 929-936. doi: 10.1016/j.jpha.2022.06.003

[33]

PETERSEN R. Strategies using bio-layer interferometry biosensor technology for vaccine research and development[J]. Biosensors, 2017, 7(4): 49. doi: 10.3390/bios7040049

[34]

Bian S, Tao Y, Zhu Z, et al. On-site biolayer interferometry-based biosensing of carbamazepine in whole blood of epileptic patients[J]. Biosensors, 2021, 11(12): 516. doi: 10.3390/bios11120516